[8-K] Verrica Pharmaceuticals Inc. Reports Material Event

Rhea-AI Filing Summary

Verrica Pharmaceuticals announced a press release reporting its financial results for the three- and six-month periods ended June 30, 2025 and disclosed details for a related conference call; that press release is furnished as Exhibit 99.1 to the current report. The filing also includes an interactive XBRL cover page file.

The company further disclosed that Nasdaq's Listing Qualifications Staff has determined the company has regained compliance with the bid price requirement under Nasdaq Listing Rule 5450(a)(1), indicating the company is currently meeting Nasdaq's listing standards for minimum bid price.

Insights

Listing Compliance Specialist

TL;DR: Nasdaq confirmed VRCA now meets the minimum bid price rule; delisting risk has been removed for now.

The notice from Nasdaq that Verrica has "regained compliance" with Rule 5450(a)(1) is material because it resolves a prior deficiency tied to the company's share price. This removes an immediate listing threat and reduces short-term regulatory uncertainty for shareholders. The filing explicitly states compliance was restored; no additional Nasdaq conditions or timelines are disclosed in the provided content.

Financial Analyst

TL;DR: Company furnished a press release with Q2 and year-to-date results and scheduled a conference call, but the filing does not include the financial details themselves.

The Form 8-K notifies investors that financial results for the three- and six-month periods ended June 30, 2025 were released via a press release (Exhibit 99.1) and a conference call will follow. The filing does not contain revenue, earnings, cash flow, or guidance figures, so no conclusions about operating performance can be drawn from this document alone.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2025 - 04:11 PM EDT Learn about SEC filing dates

false 0001660334 0001660334 2025-08-08 2025-08-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 8, 2025

Verrica Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-38529		46-3137900
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

44 W. Gay St., Suite 400 West Chester, PA		19380
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (484) 453-3300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock		VRCA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Verrica Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2025, as well as information regarding a conference call to discuss the financials and business updates. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On August 8, 2025, the Company received a letter from the Hearings Advisor of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Nasdaq Listing Qualifications Staff has determined that the Company has regained compliance with the bid price requirement in Nasdaq Listing Rule 5450(a)(1) and that the Company was therefore in compliance with Nasdaq’s listing requirements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Exhibit Description
99.1		Press Release, dated August 12, 2025
104		Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Verrica Pharmaceuticals Inc.
Date: August 12, 2025						/s/ John J. Kirby
						John J. Kirby
						Interim Chief Financial Officer